Page 2 of 3
123

pharmacokinetics (55 POSTS)

2017 (6 POSTS)

Estimated inter-individual variations in high-performance aircraft pilot exposures using physiologically-based pharmacokinetic (PBPK) modeling and Monte Carlo analysis

Covington TR, Pangburn HA, Mayes RS, Ott DK, Gearhart JM. Estimated inter-individual variations in high-performance aircraft pilot exposures using physiologically-based pharmacokinetic (PBPK) modeling and Monte Carlo analysis. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

2016 (2 POSTS)

Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes

Wilson JE, Kurukulasuriya R, Sinz C, Matthew Lombardo, Kate Bender, Dann Parker, … Dingley K, et al. 2016. Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes. Bioorg Med Chem Lett 26(12):2947–2951; doi: 10.1016/j.bmcl.2016.04.018. PMID: 27240550.

View Abstract

Predicting lung dosimetry of inhaled particle-borne benzo(a)pyrene using physiologically based pharmacokinetic modeling

Campbell J, Franzen A, Van Landingham C, Lumpkin M, Crowell S, Meredith C, Loccisano A, Gentry R, Clewell H. 2016. Predicting lung dosimetry of inhaled particle-borne benzo(a)pyrene using physiologically based pharmacokinetic modeling. Inhal Toxicol 28(11):520–535; doi: 10.1080/08958378.2016.1214768.

View Abstract

2015 (1 POST)

Application of reverse dosimetry to compare in vitro and in vivo estrogen receptor activity

Chang X, Kleinstreuer N, Ceger P, Choksi NY, Hseih J, DeVito M, Allen DG, Casey W. Application of reverse dosimetry to compare in vitro and in vivo estrogen receptor activity. Poster presented at Society of Toxicology 54th Annual Meeting, San Diego, CA, March 2015.

View Abstract

2014 (1 POST)

Refined biokinetic model for humans exposed to cobalt dietary supplements and other sources of systemic cobalt exposure

Unice KM, Kerger BD, Paustenbach DJ, Finley BL, Tvermoes BE. 2014. Refined biokinetic model for humans exposed to cobalt dietary supplements and other sources of systemic cobalt exposure. Chem-Biol Interact 216:53–74; doi: 10.1016/j.cbi.2014.04.001. PMID: 24726710.

View Abstract

2013 (2 POSTS)

Physiologically based pharmacokinetic model for humans orally exposed to chromium

Kirman CR, Aylward LL, Suh M, Harris MA, Thompson CMHaws LCProctor DM, Lin SS, Parker W, Hays SM. 2013. Physiologically based pharmacokinetic model for humans orally exposed to chromium. Chem Biol Interact 204(1):13-27; doi: 10.1016/j.cbi.2013.04.003.

View Abstract

Using PBPK modeling to address diurnal variation and age differences in hexavalent chromium toxicokinetics in humans

Kirman CR, Thompson CM, Proctor DM, Suh M, Haws LC, Harris MA, Hays SM. Using PBPK modeling to address diurnal variation and age differences in hexavalent chromium toxicokinetics in humans. Presented at Society of Toxicology 52nd Annual Meeting,San Antonio, TX, March 2013.

View Abstract

2012 (3 POSTS)

Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium

Kirman CR, Hays SM, Aylward LL, Suh M, Harris MA, Thompson CM, Haws LC, Proctor DM. 2012. Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium. Chem Biol Interact 200(1):45-64; doi: 10.1016/j.cbi.2012.08.016.

View Abstract

Physiologically-based pharmacokinetic model for mice, rats and humans orally-exposed to chromium

Kirman CR, Hays SM, Aylward LL, Suh M, Proctor D. 2012. Physiologically-based pharmacokinetic model for mice, rats and humans orally-exposed to chromium. Presented at Society of Toxicology 51st Annual Meeting, San Francisco, CA, March 2012.

View Abstract

An evaluation of single nucleotide polymorphisms in the human heat shock protein 90kDa alpha and beta isoforms

Urban J, Budinsky R, Rowlands J. 2012. An evaluation of single nucleotide polymorphisms in the human heat shock protein 90kDa alpha and beta isoforms. Drug Metab Pharmacokinet 27(2):268-278; doi: 10.2133/dmpk.DMPK-11-SC-114.

View Abstract

2011 (1 POST)

Use of mode of action and pharmacokinetic findings to inform the cancer risk assessment of ingested Cr(VI): A case study

Proctor D, Haws L, Thompson C, Harris M. 2011. Use of mode of action and pharmacokinetics to inform the cancer risk assessment of ingested Cr(VI): A case study. Presented at the Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.

View Abstract

2010 (1 POST)

Exploring issues in simulating dermal exposure using a physiologically-based pharmacokinetic-pharmacodynamic (PBPK-PD) model for VX

Covington T, Robinson P, Gearhart J. Exploring issues in simulating dermal exposure using a physiologically-based pharmacokinetic-pharmacodynamic (PBPK-PD) model for VX. Poster presented at the Chemical and Biological Defense Science and Technology Conference, Orlando, FL, November 2010.

2009 (2 POSTS)

A multi-species and -route ion- and isomer-specific physiologically-based pharmacokinetic-pharmacodynamic model for VX

Covington TR, Jakubowski EM, McGuire JM, Byers CE, Evans RA, Hulet SW, et al. A multi-species and -route ion- and isomer-specific physiologically-based pharmacokinetic-pharmacodynamic model for VX. Presentation at the Chemical and Biological Defense Science and Technology Conference, Dallas, TX, November 2009.

Database for physiologically based pharmacokinetic (PBPK) modeling: Physiological parameters for healthy and health-impaired elderly

Thompson CM, Johns DO, Sonawane S, Barton HA, Hattis D, Tardif R, Krishnan K. 2009. Database for physiologically based pharmacokinetic (PBPK) modeling: Physiological parameters for healthy and health-impaired elderly. J Toxicol Environ Health B 12(1):1–24; doi: 10.1080/10937400802545060.

View Abstract

2008 (1 POST)

Approaches for applications of physiologically based pharmacokinetic models in risk assessment

Thompson CM, Sonawane B, Barton HA, DeWoskin RS, Schlosser P, Lipscomb JC, Chiu W, Krishnan K. 2008. Approaches for applications of physiologically based pharmacokinetic models in risk assessment. J Toxicol Environ Health B 11(7):519–547; doi: 10.1080/10937400701724337.

View Abstract

2007 (2 POSTS)

A physiologically-based pharmacokinetic model for developmental exposure to PBDE-47 in rodents

Emond C, Raymer J, Garner E, Diliberto J, Staskal D, Birnbaum LS. A physiologically-based pharmacokinetic model for developmental exposure to PBDE-47 in rodents. Society of Toxicology 46th Annual Meeting, Charlotte, NC, March 2007.

A pharmacokinetic model of the intracellular dosimetry of inhaled nickel

Hack CE, Covington TR, Lawrence G, Shipp AM, Gentry R, Yager J, Clewell, HJ, III. 2007. A pharmacokinetic model of the intracellular dosimetry of inhaled nickel. J Toxicol Environ Health A 70(5):445464; doi: 10.1080/15287390600870726.

View Abstract

2006 (1 POST)

Novel fluoro-substituted campthothecins: In vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization

Rose WC, Marathe PH, Jang G, Monticello TM, Balasubramanian BN, Long B, Fairchild C, Wall ME, Wani MC. 2006. Novel fluoro-substituted campthothecins: In vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization. Cancer Chemother Pharmacol 58(1):73-85; doi: 10.1007/s00280-005-0128-y.

View Abstract

2005 (3 POSTS)

Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding and uterine tissue dose metrics of bisphenol A: A physiologically based pharmacokinetic approach

Teeguarden JG, Waechter JM Jr, Clewell HJ 3rd, Covington TR, Barton HA. 2005. Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding and uterine tissue dose metrics of bisphenol A: A physiologically based pharmacokinetic approach. Toxicol Sci 85(2):429–446; doi: 10.1093/toxsci/kfi135.

View Abstract

Data for physiologically based pharmacokinetic modeling in neonatal animals: physiological parameters in mice and Sprague-Dawley rats

Gentry PR, Haber LT, McDonald TB, Zhao Q, Covington T, Nance P, Clewell HJ III, Lipscomb JC, Barton HA. 2005. Data for physiologically based pharmacokinetic modeling in neonatal animals: Physiological parameters in mice and Sprague-Dawley rats. J Children’s Health 2(3–4):363–411; doi: 10.3109/15417060490970430.

View Abstract
Page 2 of 3
123